Skip to content

Great need for disease-modifying treatments for Alzheimer’s disease and Parkinson’s disease

At present, there are no effective treatments that can stop or delay the progression of Alzheimer’s or Parkinson’s diseases; current drugs can only alleviate the symptoms in patients over the short term. Disease-modifying treatments would therefore create significant value for patients, their families, care providers and society as a whole. This means significant commercial opportunities for new and more effective drugs.

Positive results from Phase 3 study with a drug candidate against early Alzheimer’s disease

Lecanemab showed positive results in the pivotal Phase 3 study, Clarity AD, in early Alzheimer’s disease, and both primary and all key secondary endpoints were met with high statistical significance. A rolling submission of the application for accelerated approval in the US is in progress.

Potential for the treatment of people with Alzheimer’s disease before symptoms manifest

A further comprehensive Phase 3 study is under way to evaluate the possibilities of using lecanemab to prevent the development of Alzheimer’s disease among people who have not yet manifested any clinical symptoms but have intermediate or elevated levels of amyloid in the brain.

Right to market and sell lecanemab in the Nordic region

We have right to market and sell its drug candidate lecanemab for Alzheimer’s disease in the Nordic market. BioArctic has initiated an effort to build a commercialization organization in order to exercise these rights.

Drug candidate for Parkinson’s disease ready to enter clinical Phase 2

BioArctic have a broad portfolio of alpha-synuclein antibodies with the potential to revolutionize the treatment of conditions such as Parkinson’s disease. One of these antibodies has demonstrated results that support further development in a Phase 2 study. The total value of these agreements may amount to MEUR 222 in addition to royalties. As of 30 September 2022, up to 136 MEUR in milestone payments remains from Eisai.

A strong financial position

Our business model, which generates revenue streams from signed collaboration agreements, brought us cash balances of SEK 805 million at the end of 2021. BioArctic’s strong financial position creates a high degree of flexibility and facilitates robust efforts in existing and new projects.

Employees’ specialist competence and the BioArctic’s leadership development

We are a business driven by science, with extensive expertise and experience in diseases of the brain where the aim is to slow down or, in the future, stop the progression. Our skilled employees possess invaluable specialist expertise in research and drug development. Our focus on leadership development is also an important part of our success.

Drug development based on a groundbreaking scientific discovery

BioArctic was founded based on the discovery by Professor Lars Lannfelt and his colleagues that harmful accumulations of proteins play a key role in the development of neurodegenerative disorders. This comprises the platform for our development of completely new treatments against such disorders as Alzheimer’s disease and Parkinson’s disease—work that is being carried out in close collaboration with leading academics.

Attractive projects for global pharma companies

BioArctic’s groundbreaking research, patented technology and capacity for developing disease-modifying drug candidates has facilitated broad collaborations with the global pharma company Eisai. The total value of these agreements may amount to MEUR 222 in addition to royalties. As of 30 September 2022, up to 136 MEUR in milestone payments remains from Eisai.

A project portfolio standing on several pillars

We are pursuing several early projects against Alzheimer’s disease and other disorders of the central nervous system. We are also developing a unique technology to improve the uptake of biological drugs in the brain.